Efficacy of Luteinizing Hormone (LH) Activity in Low Responder Patients With Transdermal Testosterone
Information source: Hospital Clinic of Barcelona
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Other Complications Associated With Artificial Fertilization
Intervention: Testosterone and FSHr-LHr (Drug); testosterone and FSHr alone (Drug)
Phase: N/A
Status: Active, not recruiting
Sponsored by: Hospital Clinic of Barcelona
Summary
The investigators have previously demonstrated the utility of transdermal testosterone in in
vitro fertilization (IVF) low responder patients. Now, the investigators want to evaluate
the efficacy of luteinizing hormone (LH) activity added to recombinant follicular
stimulating hormone (FSHr) during ovarian stimulation in these patients.
Clinical Details
Official title: Efficacy of LH Activity in Low Responder Patients With Transdermal Testosterone: a Randomised Controlled Study.
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment
Primary outcome: ovarian response
Secondary outcome: clinical pregnancy rateImplantation rate Live birth rate
Detailed description:
Studies in macaques have indicated that androgens have some synergistic effects with
follicular stimulating hormone (FSH) on folliculogenesis. Our previous clinical studies
demonstrated the usefulness of pretreatment with transdermal testosterone in low-responder
IVF patients.
There is controversy on the usefulness of recombinant luteinizing hormone (LHr) added to
FSHr in ovarian stimulation of low responder patients. Thus, our present study has been
designed to compare ovarian stimulation with FSHr alone versus LHr added to FSHr when
transdermal testosterone pretreatment is used.
Eligibility
Minimum age: 18 Years.
Maximum age: 41 Years.
Gender(s): Female.
Criteria:
Inclusion Criteria:
- Low responder patients: patients with previously canceled cycle or recovery of 3 or
less oocytes
Exclusion Criteria:
- FSH > 12
- Previous ovarian surgery
Locations and Contacts
Hospital Clínic, Barcelona 08036, Spain
Additional Information
Related publications: Balasch J, Fábregues F, Peñarrubia J, Carmona F, Casamitjana R, Creus M, Manau D, Casals G, Vanrell JA. Pretreatment with transdermal testosterone may improve ovarian response to gonadotrophins in poor-responder IVF patients with normal basal concentrations of FSH. Hum Reprod. 2006 Jul;21(7):1884-93. Epub 2006 Mar 3.
Starting date: January 2011
Last updated: February 7, 2011
|